Topotecan
17 interactionsTopotecan is used to treat small cell lung cancer (a type of cancer that begins in the lungs) that was successfully treated with a different chemotherapy medication but has returned no sooner than 45 days after the last dose of the first chemotherapy medication was taken. Topotecan is in a class of medications called t… Read the full Topotecan drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Topotecan Asciminib Scemblix Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse effects Details Topotecan Capmatinib Tabrecta Risk of increased adverse reactions Details Topotecan Cyclosporine Injection Atopica Increased topotecan exposure and risk of adverse events Details Topotecan Cyclosporine Ophthalmic Cequa Increased topotecan exposure and risk of adverse events Details Topotecan Darolutamide Nubeqa Increased plasma concentrations of BCRP substrates Details Topotecan Elacestrant Orserdu Increased topotecan exposure and risk of adverse events Details Topotecan Enasidenib Idhifa Increased topotecan exposure and risk of adverse events Details Topotecan Febuxostat Uloric Increased topotecan exposure and risk of adverse events Details Topotecan Fostamatinib Tavalisse Increased topotecan exposure and risk of adverse events Details Topotecan Fostemsavir Rukobia Increased topotecan exposure and risk of adverse events Details Topotecan Ketoconazole Topical Extina® Foam Increased topotecan exposure and risk of adverse events Details Topotecan Leflunomide Arava Increased exposure of BCRP substrate Details Topotecan Lenacapavir Injection Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Topotecan Lenacapavir Oral Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Topotecan Leniolisib Joenja Increased BCRP substrate exposure Details Topotecan Midostaurin Rydapt Increased BCRP substrate exposure DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist